These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23360924)

  • 41. ROMA, an algorithm for ovarian cancer.
    Chudecka-Głaz AM
    Clin Chim Acta; 2015 Feb; 440():143-51. PubMed ID: 25447706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HE4 can help discriminate women with malignant ovarian 
tumors only if CA125 levels are elevated.
    Pitta Dda R; Sarian LO; Campos EA; Andrade LL; Sallum LF; Bragança JF; Campos Cde M; Derchain S
    Int J Biol Markers; 2013; 28(4):e377-86. PubMed ID: 23828407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors.
    Janas L; Stachowiak G; Glowacka E; Piwowarczyk I; Kajdos M; Soja M; Masternak M; Nowak M
    Ginekol Pol; 2024; 95(5):321-327. PubMed ID: 36597746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study.
    Sundar S; Agarwal R; Davenport C; Scandrett K; Johnson S; Sengupta P; Selvi-Vikram R; Kwong FL; Mallett S; Rick C; Kehoe S; Timmerman D; Bourne T; Van Calster B; Stobart H; Neal RD; Menon U; Gentry-Maharaj A; Sturdy L; Ottridge R; Deeks J;
    Lancet Oncol; 2024 Oct; 25(10):1371-1386. PubMed ID: 39362250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses].
    Janas L; Głowacka E; Wilczyński JR; Malinowski A; Nowak M
    Ginekol Pol; 2015 Mar; 86(3):193-7. PubMed ID: 25920309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective evaluation of IOTA logistic regression models LR1 and LR2 in comparison with subjective pattern recognition for diagnosis of ovarian cancer in an outpatient setting.
    Nunes N; Ambler G; Foo X; Widschwendter M; Jurkovic D
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):829-835. PubMed ID: 28976616
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.
    Moore RG; Jabre-Raughley M; Brown AK; Robison KM; Miller MC; Allard WJ; Kurman RJ; Bast RC; Skates SJ
    Am J Obstet Gynecol; 2010 Sep; 203(3):228.e1-6. PubMed ID: 20471625
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.
    Choi HJ; Lee YY; Sohn I; Kim YM; Kim JW; Kang S; Kim BG
    Curr Probl Cancer; 2020 Apr; 44(2):100508. PubMed ID: 31708114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
    Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies.
    Kaijser J; Bourne T; Valentin L; Sayasneh A; Van Holsbeke C; Vergote I; Testa AC; Franchi D; Van Calster B; Timmerman D
    Ultrasound Obstet Gynecol; 2013 Jan; 41(1):9-20. PubMed ID: 23065859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
    Abdalla N; Piorkowski R; Bachanek M; Stanirowski P; Cendrowski K; Sawicki W
    Dis Markers; 2018; 2018():5289804. PubMed ID: 29849823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
    Zhang L; Chen Y; Wang K
    Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
    Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
    J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses.
    Yang Y; Ju H; Huang Y
    Eur J Radiol; 2023 Aug; 165():110926. PubMed ID: 37418798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.
    Yu S; Lee JK; Kim JH; Park H; Lee MY; Ryu S; Kwon MJ; Woo HY
    Gynecol Oncol; 2016 Oct; 143(1):128-134. PubMed ID: 27426308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HE4 and ROMA index in Czech postmenopausal women.
    Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z
    Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.